Indications for: INBRIJA
Intermittent treatment of OFF episodes in patients with Parkinson's disease treated with carbidopa/levodopa.
For oral inh only; use with Inbrija inhaler. Do not swallow caps. Inhale contents of 2 caps (84mg) as needed, up to 5 times daily. Max dose per OFF period: 84mg; max daily dose: 420mg.
During or within 14 days of nonselective MAOIs (eg, phenelzine, tranylcypromine).
Sleep disorders: consider discontinuing if significant daytime sleepiness occurs. Withdrawal-emergent hyperpyrexia or confusion: avoid rapid dose reduction, withdrawal of, or changes in dopaminergic therapy. Increased risk of hallucinations and psychosis. Major psychotic disorder, asthma, COPD, chronic lung disease: not recommended. Impulse control disorders: consider discontinuing if occurs. Glaucoma: monitor IOP. Pregnancy. Nursing mothers.
See Contraindications. Orthostatic hypotension with MAO-B inhibitors; monitor. Antagonized by dopamine D2 receptor antagonists (eg, phenothiazines, butyrophenones, risperidone, metoclopramide), isoniazid, iron salts; monitor. May cause false (+) plasma/urine results suggesting pheochromocytoma.
Cough, nausea, upper respiratory tract infection, sputum discolored; dyskinesia (adjust doses), CNS disturbances (eg, hallucinations, confusion, somnolence), bronchospasm, increased IOP, lab abnormalities.
Generic Drug Availability:
Caps (w. inhaler)—60, 92